SCHEMBL3566489

SCHEMBL3566489

CN(C)N=C1C=CC(NC(=O)C(NC(=O)Nc2ccc(Cl)cc2)c2ccccc2Cl)=CC1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 6/20 0.37
CNR1 P21554 3/20 0.36
MEN1 O00255 4/20 0.35
KMT2A Q03164 4/20 0.35
NPC1 O15118 4/20 0.35
MAPT P10636 4/20 0.35
RAB9A P51151 4/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
LMNA P02545 3/20 0.35
ALDH1A1 P00352 2/20 0.35
GAA P10253 2/20 0.34
KDM4E B2RXH2 1/20 0.34
POLB P06746 1/20 0.34
MAPK1 P28482 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
HTT P42858 2/20 0.34
P2RY1 P47900 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3564411 0.92 CNR1 (0.36) UTS2RCNR1MEN1KMT2ANPC1
SCHEMBL3560347 0.92 RAB9A (0.38) UTS2RCNR1MEN1KMT2ANPC1
SCHEMBL3564560 0.91 UTS2R (0.36) UTS2RCNR1MEN1KMT2ANPC1
SCHEMBL3573284 0.91 CNR1 (0.36) UTS2RCNR1MEN1KMT2ANPC1
SCHEMBL3564975 0.90 LMNA (0.40) UTS2RCNR1MEN1KMT2ANPC1
SCHEMBL3559267 0.90 FPR2 (0.42) UTS2RCNR1MEN1KMT2AMAPT
SCHEMBL3567171 0.84 HTT (0.42) UTS2RCNR1MEN1KMT2ANPC1
SCHEMBL3560764 0.84 SMN1; SMN2 (0.36) CNR1MEN1KMT2ANPC1MAPT
SCHEMBL3570284 0.81 FPR2 (0.43) CNR1MEN1KMT2ANPC1MAPT
SCHEMBL3567078 0.81 MAPT (0.43) UTS2RCNR1MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US claimed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US claimed
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US disclosed
WO-2006063113-A2 UREAS AS FACTOR XA INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160821-A1 Ureas as factor Xa inhibitors TFPI, F12, F11 UTS2R 52/4885CNR1 1500/4885MEN1 2311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.